SONA Asset Management (US)’s BioMarin Pharmaceuticals BMRN Stock Holding History

SONA Asset Management (US)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,400	Closed	-$309K	–	96
2024 Q3	$309K	Hold	4,400	–	–	0.01%	97
2024 Q2	$362K	Buy	4,400 +1,100	+33%	+$91.6K	0.01%	70
2024 Q1	$288K	Hold	3,300	–	–	0.01%	66
2023 Q4	$318K	Sell	3,300 -9,800	-75%	-$867K	0.01%	50
2023 Q3	$1.17M	Buy	+13,100	New	+$1.17M	0.05%	40
2023 Q1	–	Sell	-7,650	Closed	-$792K	–	166
2022 Q4	$792K	Hold	7,650	–	–	0.23%	39
2022 Q3	$648K	Sell	7,650 -525	-6%	-$46.7K	0.38%	51
2022 Q2	$679K	Buy	+8,175	New	+$651K	0.66%	43

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

SONA Asset Management (US)'s BMRN Position: Q4 2024 in Review

SONA Asset Management (US) sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 4,400 shares — an estimated $309K sold.

SONA Asset Management (US) first reported a position in BMRN in Q2 2022 and held it in 8 quarters. The position peaked at $1.17M in Q3 2023. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

SONA Asset Management (US) reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
SONA Asset Management (US) sold 4,400 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $309K.
SONA Asset Management (US) first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 8 quarters.
SONA Asset Management (US)'s BioMarin Pharmaceuticals position peaked at $1.17M in Q3 2023.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on SONA Asset Management (US)'s 13F filing for Q4 2024, filed 14 Feb 2025.